Nowadays, a very large number of patients suffer from chronic prostatitis and benign prostatic hyperplasia (BPH). In the daily practice of urologists, these diseases take up almost 95% of all the symptomatics. With such high incidence rates, various drugs can be used in clinical practice. In addition to chemical drugs, there are biological ones that are actively used in therapy. Moreover, today more and more patients prefer biological drugs, fearing certain adverse effects that sometimes occur in traditional chemical drugs.

One of such biological preparations is Adenoprosin®, an original European drug used for the treatment of BPH and chronic prostatitis. The active substance of the product contains lipoproteins, which are obtained from insect larvae of the Lymantria dispar species (the gypsy moth). The obtained biomass has antioxidant, vascular protective, anti-inflammatory and immunomodulation properties. The effectiveness of the drug is determined by the cumulative effect of the active components of the biological mass.

Under the action of Adenoprosin®, the size of the prostate gland decreases due to the induction of apoptosis; the growth of prostate gland cells is inhibited and the antioxidant effect is achieved due to the reduction of intracellular hydrogen peroxide; the anti-inflammatory effect is manifested due to the inhibition of extracellular pro-inflammatory cytokines and anti-angiogenic effect; apoptosis is inhibited when the cells are in inflammatory environment. In general, the drug demonstrates the following properties:

  • Reduction of symptoms of BPH;
  • Improvement of urodynamics;
  • Reduction of the size of the hyperplastic prostate.